Animal Health Industry Update: Reflections on the past year | Kisaco Research

The past 12 months have seen rapid innovation and transformation across the Animal Health industry. Stonehaven Cozmix Group explores advancements in technology and business models shaping the sector’s future, including

  • Major launches – Spotlight on new launches in Companion Animal dermatology, cardiology, and parasiticides and Farm Animal vaccines
  • Generics Landscape – Evolving competition and market dynamics
  • Business Activity – Notable M&A transactions and start-up funding
  • Innovative Models – Emerging business approaches reshaping customer engagement and routes to commercialisation
  • AI in Animal Health – Growing applications across R&D, diagnostics, and decision-making.
Sponsor(s): 
Stonehaven Cozmix Group
Speaker(s): 

Author:

Matthias Hofer

Managing Partner
Stonehaven Cozmix Group

Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Matthias Hofer

Managing Partner
Stonehaven Cozmix Group

Matthias Hofer is the Managing Partner at Stonehaven Consulting AG with over 15 years of experience in Animal Health. He served on the executive committees of two major Animal Health companies for a total of 7 years. Between 2009 and 2013 he led the global Aqua Health business at Novartis Animal Health (NAH). Later on, he was Global Leader Emerging Business at Elanco and a member of Elanco’s global executive committee. During 2014 and with Elanco’s intention to buy NAH, Matthias served as overall pre-merger integration leader on the Novartis side. In that role, Matthias led a large team and efforts to prepare integration pre-closing overall including carve-out preparations of operations linked to Novartis.

Author:

Chad Terrell

Head of Business Development
Stonehaven Cozmix Group

Chad Terrell

Head of Business Development
Stonehaven Cozmix Group
Time: 
9:05am - 9:25am
Session Type: 
General Session (Presentation)